These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 28613437)

  • 1. T Cell Subsets Predicting Belatacept-Resistant Rejection: Finding the Root Where the Trouble Starts.
    Wekerle T
    Am J Transplant; 2017 Sep; 17(9):2235-2237. PubMed ID: 28613437
    [No Abstract]   [Full Text] [Related]  

  • 2. Belatacept-Resistant Rejection Is Associated With CD28
    Mathews DV; Wakwe WC; Kim SC; Lowe MC; Breeden C; Roberts ME; Farris AB; Strobert EA; Jenkins JB; Larsen CP; Ford ML; Townsend R; Adams AB
    Am J Transplant; 2017 Sep; 17(9):2285-2299. PubMed ID: 28502128
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Increased Pretransplant Frequency of CD28
    Cortes-Cerisuelo M; Laurie SJ; Mathews DV; Winterberg PD; Larsen CP; Adams AB; Ford ML
    Am J Transplant; 2017 Sep; 17(9):2350-2362. PubMed ID: 28502091
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Postdepletion Lymphocyte Reconstitution During Belatacept and Rapamycin Treatment in Kidney Transplant Recipients.
    Xu H; Samy KP; Guasch A; Mead SI; Ghali A; Mehta A; Stempora L; Kirk AD
    Am J Transplant; 2016 Feb; 16(2):550-64. PubMed ID: 26436448
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Secondary lymphoid tissue and costimulation-blockade resistant rejection: A nonhuman primate renal transplant study.
    Mulvihill MS; Samy KP; Gao QA; Schmitz R; Davis RP; Ezekian B; Leopardi F; Song M; How T; Williams K; Barbas A; Collins B; Kirk AD
    Am J Transplant; 2019 Aug; 19(8):2350-2357. PubMed ID: 30891931
    [TBL] [Abstract][Full Text] [Related]  

  • 6. TIGIT regulates apoptosis of risky memory T cell subsets implicated in belatacept-resistant rejection.
    Sun H; Hartigan CR; Chen CW; Sun Y; Tariq M; Robertson JM; Krummey SM; Mehta AK; Ford ML
    Am J Transplant; 2021 Oct; 21(10):3256-3267. PubMed ID: 33756063
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Alloreactive CD154-expressing T-cell subsets with differential sensitivity to the immunosuppressant, belatacept: potential targets of novel belatacept-based regimens.
    Ashokkumar C; Ganguly B; Townsend R; White J; Levy S; Moritz M; Mazariegos G; Sun Q; Sindhi R
    Sci Rep; 2015 Oct; 5():15218. PubMed ID: 26472085
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunological Characteristics of a Patient With Belatacept-Resistant Acute Rejection After Face Transplantation.
    Krezdorn N; Murakami N; Pomahac B; Riella LV
    Am J Transplant; 2016 Nov; 16(11):3305-3307. PubMed ID: 27457067
    [No Abstract]   [Full Text] [Related]  

  • 9. Siplizumab combination therapy with belatacept or abatacept broadly inhibits human T cell alloreactivity in vitro.
    Cvetkovski F; Razavi R; Sellberg F; Berglund E; Berglund D
    Am J Transplant; 2023 Oct; 23(10):1603-1611. PubMed ID: 37270108
    [TBL] [Abstract][Full Text] [Related]  

  • 10. IL-7 receptor heterogeneity as a mechanism for repertoire change during postdepletional homeostatic proliferation and its relation to costimulation blockade-resistant rejection.
    Xu H; Bendersky VA; Brennan TV; Espinosa JR; Kirk AD
    Am J Transplant; 2018 Mar; 18(3):720-730. PubMed ID: 29136317
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anti-CD28 Antibody and Belatacept Exert Differential Effects on Mechanisms of Renal Allograft Rejection.
    Ville S; Poirier N; Branchereau J; Charpy V; Pengam S; Nerriere-Daguin V; Le Bas-Bernardet S; Coulon F; Mary C; Chenouard A; Hervouet J; Minault D; Nedellec S; Renaudin K; Vanhove B; Blancho G
    J Am Soc Nephrol; 2016 Dec; 27(12):3577-3588. PubMed ID: 27160407
    [TBL] [Abstract][Full Text] [Related]  

  • 12. TIGIT agonism alleviates costimulation blockade-resistant rejection in a regulatory T cell-dependent manner.
    Hartigan CR; Tong KP; Liu D; Laurie SJ; Ford ML
    Am J Transplant; 2023 Feb; 23(2):180-189. PubMed ID: 36695691
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Belatacept Combined With Transient Calcineurin Inhibitor Therapy Prevents Rejection and Promotes Improved Long-Term Renal Allograft Function.
    Adams AB; Goldstein J; Garrett C; Zhang R; Patzer RE; Newell KA; Turgeon NA; Chami AS; Guasch A; Kirk AD; Pastan SO; Pearson TC; Larsen CP
    Am J Transplant; 2017 Nov; 17(11):2922-2936. PubMed ID: 28544101
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Selective Targeting of High-Affinity LFA-1 Does Not Augment Costimulation Blockade in a Nonhuman Primate Renal Transplantation Model.
    Samy KP; Anderson DJ; Lo DJ; Mulvihill MS; Song M; Farris AB; Parker BS; MacDonald AL; Lu C; Springer TA; Kachlany SC; Reimann KA; How T; Leopardi FV; Franke KS; Williams KD; Collins BH; Kirk AD
    Am J Transplant; 2017 May; 17(5):1193-1203. PubMed ID: 27888551
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Costimulation Blockade in Kidney Transplantation: Beyond Belatacept.
    Rostaing L; Malvezzi P
    Transplantation; 2016 Dec; 100(12):2516-2518. PubMed ID: 27525642
    [No Abstract]   [Full Text] [Related]  

  • 16. A pilot trial targeting the ICOS-ICOS-L pathway in nonhuman primate kidney transplantation.
    Lo DJ; Anderson DJ; Song M; Leopardi F; Farris AB; Strobert E; Chapin S; Devens B; Karrer E; Kirk AD
    Am J Transplant; 2015 Apr; 15(4):984-92. PubMed ID: 25703015
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Optimization of de novo belatacept-based immunosuppression administered to renal transplant recipients.
    Kirk AD; Adams AB; Durrbach A; Ford ML; Hildeman DA; Larsen CP; Vincenti F; Wojciechowski D; Woodle ES
    Am J Transplant; 2021 May; 21(5):1691-1698. PubMed ID: 33128812
    [TBL] [Abstract][Full Text] [Related]  

  • 18. FcγRIIB, a new checkpoint to halt alloreactive memory T cells.
    Cravedi P
    Am J Transplant; 2020 Aug; 20(8):1967-1968. PubMed ID: 32185851
    [No Abstract]   [Full Text] [Related]  

  • 19. Selective CD28 Blockade Results in Superior Inhibition of Donor-Specific T Follicular Helper Cell and Antibody Responses Relative to CTLA4-Ig.
    Badell IR; La Muraglia GM; Liu D; Wagener ME; Ding G; Ford ML
    Am J Transplant; 2018 Jan; 18(1):89-101. PubMed ID: 28637095
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Belatacept/CTLA4Ig: an update and critical appraisal of preclinical and clinical results.
    Schwarz C; Mahr B; Muckenhuber M; Wekerle T
    Expert Rev Clin Immunol; 2018 Jul; 14(7):583-592. PubMed ID: 29874474
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.